John Hughes

Q: What Schools Are Affiliated With John Hughes

John Hughes is affiliated with the following schools: Imperial College London, University of Oxford, University of Aberdeen, King's College London

John Hughes 's AcademicInfluence.com Rankings

John Hughes

Medical

#814

World Rank

#1066

Historical Rank

Pharmacology

#190

World Rank

#230

Historical Rank

medical Degrees

Download Badge

Medical

John Hughes 's Degrees

PhD Pharmacology University of Oxford
Bachelors Pharmacology University of Oxford

Why Is John Hughes Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John Hughes is a British neuroscientist who shared the 1978 Albert Lasker Award for Basic Medical Research for the discovery of met-enkephalin and leu-enkephalin. This discovery demonstrated that opiate drugs exert their effects on the human brain by mimicking endogenous neurotransmitters, the opioid peptides.

(See a Problem?)

John Hughes 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of two related pentapeptides from the brain with potent opiate agonist activity (1975) (3549)
Endogenous opioid peptides: multiple agonists and receptors (1977) (2411)
Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine (1975) (973)
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. (1990) (477)
EFFECT OF MORPHINE ON ADRENERGIC TRANSMISSION IN THE MOUSE VAS DEFERENS. ASSESSMENT OF AGONIST AND ANTAGONIST POTENCIES OF NARCOTIC ANALGESICS (1975) (391)
Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agents (1997) (355)
THE DISTRIBUTION OF METHIONINE‐ENKEPHALIN AND LEUCINE‐ENKEPHALIN IN THE BRAIN AND PERIPHERAL TISSUES (1997) (311)
Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat (1999) (308)
Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. (1997) (284)
Some thoughts on the significance of enkephalin, the endogenous ligand. (1975) (267)
Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation (1971) (207)
Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? (1999) (198)
In vitro pharmacology of the opioid peptides, enkephalins and endorphins. (1977) (197)
κ‐Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat (1988) (191)
Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices (2001) (191)
Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. (1991) (190)
A new example of a morphine‐sensitive neuro‐effector junction: Adrenergic transmission in the mouse vas deferens (1997) (183)
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. (1990) (171)
The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin (1988) (158)
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. (1991) (154)
Cholecystokinin Modulates the Release of Dopamine from the Anterior and Posterior Nucleus Accumbens by Two Different Mechanisms (1991) (151)
In vitro release of Leu- and Met-enkephalin from the corpus striatum (1978) (150)
The behavioural properties of CI‐988, a selective cholecystokininB receptor antagonist (1991) (138)
Evaluation of mechanisms controlling the release and inactivation of the adrenergic transmitter in the rabbit portal vein and vas deferens (1972) (133)
Cross tolerance between morphine and methionine-enkephalin (1976) (128)
CI‐977, a novel and selective agonist for the κ‐opioid receptor (1990) (123)
An analysis of the responses of the isolated portal vein of the rabbit to electrical stimulation and to drugs. (1967) (117)
Further evidence for the role of the α2δ subunit of voltage dependent calcium channels in models of neuropathic pain (2000) (104)
Anxiolytic effects of CCK-B antagonists (1991) (96)
Functional role of brain CCK receptors (1991) (94)
Pharmacological profile of PD 117302, a selective κ‐opioid agonist (1987) (87)
Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: Effects of naloxone and peptidase inhibitors (1987) (83)
CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat (1992) (79)
Cholecystokinin antagonists. (1991) (77)
THE EFFECTS OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM THE CAT ISOLATED NICTITATING MEMBRANE AND THE GUINEA‐PIG ILEUM MYENTERIC PLEXUS‐LONGITUDINAL MUSCLE PREPARATION (1975) (76)
THE EFFECTS OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM THE MOUSE VAS DEFERENS (1976) (75)
Opioid Peptides: introduction. (1983) (73)
PD117302: a selective agonist for the κ‐opioid receptor (1988) (68)
Acceleration of noradrenaline biosynthesis in the guinea‐pig vas deferens by potassium (1970) (65)
Incorporation of labelled amino acids into the enkephalins (1977) (64)
Structure‐activity relationships of methionine‐enkephalin (1976) (62)
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. (1993) (61)
Angiotensin accelerates Catecholamine Biosynthesis in Sympathetically Innervated Tissues (1969) (59)
Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. (2000) (59)
Relaxations of the isolated portal vein of the rabbit induced by nicotine and electrical stimulation (1970) (59)
The neuroprotective effects of the recombinant interleukin–1 receptor antagonist rhIL–1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene (1998) (57)
Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives. (1988) (56)
VARIATION IN NORADRENALINE OUTPUT WITH CHANGES IN STIMULUS FREQUENCY AND TRAIN LENGTH: ROLE OF DIFFERENT NORADRENALINE POOLS (1974) (50)
Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives. (1990) (48)
The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. (1997) (47)
The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats. (1994) (46)
Peptides with Morphine-like Action in the Brain (1977) (44)
Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists. (1996) (44)
Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. (2000) (43)
PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. (1998) (42)
Rationally Designed “Dipeptoid” Analogues of CCK. α-Methyltryptophan Derivatives as Highly Selective and Orally Active Gastrin and CCK-B Antagonists with Potent Anxiolytic Properties. (1991) (42)
α-Methyl tryptophanylphenylalanines and their arylethylamine dipeptoid analogues of the tetrapeptide cholecystokinin (30-33) (1990) (39)
Prolonged Changes in Neurochemistry of Dopamine Neurones After Chronic Ethanol Consumption (2000) (39)
The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat (1991) (39)
THE DISTRIBUTION OF METHIONINE‐ENKEPHALIN AND LEUCINE‐ENKEPHALIN IN THE BRAIN AND PERIPHERAL TISSUES (1977) (36)
In vivo evidence for spinal delta-opiate receptor-operated antinociception (1986) (35)
Differential labelling of intraneuronal noradrenaline stores with different concentrations of (–)‐3H‐noradrenaline (1973) (34)
Ketanserin antagonises the anorectic effect of DL-fenfluramine in the rat. (1988) (34)
The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI‐988 (1992) (34)
EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. (1997) (34)
Correlation of ontogeny with function of [3H]U69593 labelled κ opioid binding sites in the rat spinal cord (1989) (33)
Inhibition of noradrenaline release by lysergic acid diethylamide (1973) (32)
PD117302, a selective non-peptide opioid kappa agonist, protects against NMDA and maximal electroshock convulsions in rats. (1990) (32)
The anticonvulsant action of CI-977, a selective kappa-opioid receptor agonist: a possible involvement of the glycine/NMDA receptor complex. (1990) (31)
Differences in the inhibitory effects of normorphine and opioid peptides on the responses of the vasa deferentia of two strains of mice. (1978) (31)
CCK 8 analgesia and hyperalgesia after intrathecal administration in the rat: Comparison with CCK-related peptides (1987) (30)
Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists (1991) (30)
PD 165929 — the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist (1996) (30)
Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain. (1998) (29)
Pharmacology identification of two related pentapeptides from the brain with potent opiate agonist activity Nature (Lond.), 258 (1975) 577–579 (1976) (29)
Neuropeptides. Function and clinical applications. (1992) (28)
MODIFICATION OF CATECHOLAMINE RELEASE BY NARCOTIC ANALGESICS AND OPIOID PEPTIDES (1979) (28)
Rational design of high affinity tachykinin NK2 receptor antagonists. (1994) (28)
The variation of noradrenaline output with frequency of nerve stimulation and the effect of morphine on the cat nictitating membrane and on the guinea-pig myenteric plexus. (1972) (26)
Highly selective kappa-opioid analgesics. 2. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives. (1989) (25)
The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design (1994) (25)
Quipazine reduces food intake in the rat by activation of 5‐HT2‐receptors (1988) (25)
An in vitro profile of activity for the (+) and (-) enantiomers of spiradoline and PD117302. (1989) (24)
Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat. (1998) (24)
Development of the concepts of opiate receptors and their ligands. (1978) (24)
Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat (1993) (23)
[3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. (1993) (21)
A Kinetic Analysis of k‐Opioid Agonist Binding Using the Selective Radioligand [3H]U69593 (1989) (21)
Bradykinin-induced accumulation of [3H]inositol-1-phosphate in human embryonic pituitary tumour cells by activation of a B2-receptor (1988) (21)
L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity (1989) (21)
δ‐Opioid receptor binding sites in rodent spinal cord (1990) (20)
Acceleration of catecholamine biosynthesis in sympathetically innervated tissues by angiotensin‐II‐amide (1972) (20)
The kappa agonists PD117302 and U50488 produce a biphasic effect on 24 hour food intake in the rat (1987) (18)
Characterization of novel peptoid agonists for the CCK-A receptor (1996) (18)
Enhanced release of transmitter during sympathetic nerve stimulation in the presence of angiotensin. (1969) (17)
Proceedings: Assessment of the agonist and antagonist activities of narcotic analgesic drugs by means of the mouse vas deferens. (1974) (17)
Acceleration of protein synthesis by angiotensin--correlation with angiotensin's effect on catecholamine biosynthesis. (1972) (17)
Characterization of cholecystokinin octapeptide‐stimulated endogenous dopamine release from rat nucleus accumbens in vitro (1990) (16)
Proceedings: Modulation of frequency-dependent noradrenaline release by calcium, angiotensin and morphine. (1974) (16)
Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases (1989) (16)
Quantitative analysis of autoradiograms. (1989) (14)
CCK in Cerebral Cortex and at the Spinal Level a (1994) (14)
Kappa opioid binding sites in the dog cerebral cortex and spinal cord (1989) (13)
PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. (1993) (13)
Highly selective kappa opioid analgesics. 4. Synthesis of some conformationally restricted naphthalene derivatives with high receptor affinity and selectivity. (1991) (12)
Solubilization and characterisation of the cholecystokininB binding site from pig cerebral cortex. (1989) (12)
Pharmacological and biochemical aspects of the enkephalins (1978) (12)
Intrathecal injection of a ϰ opioid agonist produces hyperalgesia in the guinea pig (1988) (12)
Opioid binding sites in the guinea pig and rat kidney: radioligand homogenate binding and autoradiography. (1991) (12)
Antagonism of central and peripheral anorectic effects of caerulein by L-364,718. (1989) (10)
A possible role for prostaglandins in the expression of morphine dependence in guinea‐pig isolated ileum (1988) (10)
Effects of 5-HT and alpha1 adrenoceptor antagonists on kappa opioid-induced sedation (1988) (9)
[125I]Dynorphin(1–8) produces a similar pattern of κ-opioid receptor labelling to [3H]dynorphin(1–8) and [3H]etorphine in guinea pig brain: A quantitative autoradiographic study (1988) (9)
Enkephalin release from the myenteric plexus of the guinea-pig small intestine in the presence of cycloheximide [proceedings]. (1978) (9)
Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin (1991) (9)
The anticonvulsant properties of antisense c-fos oligodeoxynucleotides in kainic acid-induced seizures (1997) (8)
Opiate receptors and endogenous opioid peptides in tolerance and dependence. (1977) (8)
The effects of the kappa agonist PD-117302 on feeding behaviour in obese and lean Zucker rats (1988) (8)
Cholecystokinin releases [3H]GABA from the perfused subarachnoid space of the anaesthetized rat spinal cord (1987) (8)
The incorporation of [3H]-tyrosine into the enkephalins of striatal slices of guinea-pig brain [proceedings]. (1978) (7)
PD117302: a selective agonist for the kappa-opioid receptor. (1988) (7)
Pharmacological profile of PD 117302, a selective kappa-opioid agonist. (1987) (7)
Activation of c-fos mRNA in the brain by the kappa-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine. (1997) (6)
The detection and assay of noradrenaline released from isolated tissues during intramural nerve stimulation. (1970) (6)
Anticonvulsant agents, dizocilpine maleate, enadoline and ha 966 have different effects onn-methyl-dl-aspartate-induced immediate early gene induction in mice (1993) (6)
Variations in noradrenaline output with respect to stimulus frequency, train length and origin of the transmitter. (1972) (6)
Further evidence for the role of the a 2 d subunit of voltage dependent calcium channels in models of neuropathic pain (5)
A new example of a morphine‐sensitive neuro‐effector junction: adrenergic transmission in the mouse vas deferens (1972) (5)
PD 165929 - The First High Affinity Non-Peptide Neuromedin-B (NMB) Receptor Selective Antagonist. (1997) (5)
A Comparison of the Effects of Bombesin Seen in the Isolated Ileum and Colon of the Guinea Pig (1988) (4)
The distribution of methionine‐enkephalin and leucine‐enkephalin in the brain and peripheral tissues (1997) (4)
Intrathecal injection of a kappa opioid agonist produces hyperalgesia in the guinea pig. (1988) (4)
Rationally designed "dipeptoid" analogs of CCK. .alpha.-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties [Erratum to document cited in CA114(5):43545w] (1991) (3)
Comparison of the effects of calcium concentration on mu and kappa agonist actions in the guinea pig ileum. (1986) (3)
Which Subtype(s) of 5‐HT Receptor Mediates the Anorectic Effects of Drugs That Act via the 5‐HT System? (1989) (3)
Biological Significance of the Endogenous Opioid Peptides and the Opiate Receptors (1978) (3)
The Rational Development of Small Molecule Tachykinin NK3 Receptor Selective Antagonists ‐ The Utilization of a Dipeptide Chemical Library in Drug Design. (1995) (3)
Opioid peptides. (1977) (2)
The inhibitory effects of clonidine on the contractions of the guinea-pig ileum in the morphine-dependent and withdrawn states [proceedings]. (1978) (2)
THEEFFECTSOF MORPHINEON THE RELEASEOF NORADRENALINEFROM THECATISOLATEDNICTITATING MEMBRANE AND THEGUINEA-PIG ILEUMMYENTERIC PLEXUS-LONGITUDINAL MUSCLEPREPARATION (1975) (2)
Evaluation of neuronal and extraneuronal uptake mechanisms during adrenergic nerve stimulation. (1971) (2)
Characterization of kappa-opioid receptors in the guinea-pig ileum. (1990) (2)
Pd 117302 attenuates glutamate neurotoxicity in vitro (1990) (1)
Release of (3 H)-Gaba by CCK-8 from the perfused subarachnoid space of the anaesthetised rat (1987) (1)
Differential labelling of intra-neuronal noradrenaline stores with different concentrations of (-)-3 H-noradrenaline (2006) (1)
PD 117302, a novel kappa opioid agonist (1987) (1)
Potention by veratrine of the responses of isolated vascular tissue to tyramine and sympathetic nerve stimulation (2004) (1)
Evidence foraninvolvement ofthebrain cholecystokinin B receptor inanxiety (1991) (1)
A synergistic combination of NK-1 receptor antagonists and gaba analog (2000) (0)
CI-977, A novel, selective and exceptionally potent kappa opioid agonist (1990) (0)
The CCKB antagonist CI988 enhances the analgesic effect of morphine in rats with neuropathic pain (1994) (0)
EFFECTOF MORPHINEON ADRENERGIC TRANSMISSIONINTHE MOUSE VAS DEFERENS.ASSESSMENTOF AGONISTAND ANTAGONISTPOTENCIESOF NARCOTICANALGESICS (1975) (0)
A new example of a morphine‐sensitive neuro‐effector junction: adrenergic transmission in the mouse vas deferens (1997) (0)
A comparison of the responses to bombesin seen in the isolated ileum and colon of the guinea pig (1987) (0)
Enkepshalins: Peptide Neurotransmitters Acting at Opiate Receptors (1977) (0)
PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment (2016) (0)
434 ANTINOCICEPTIVE EFFECTS OF A SELECTIVE ERBETA AGONIST THROUGH MODULATION OF THE ENDOGENOUS OPIOID SYSTEM (2009) (0)
Acceleration of the rate limiting step in norepinephrine biosynthesis by potassium (1970) (0)
Centrum cholecystokinin antagonist having pharmaceutical activity (1990) (0)
Pharmacol . ( 1988 ) , 93 , 618-626 PD 1 17302 : a selective agonist for the ic-opioid receptor 2 (2006) (0)
Potentiation by veratrine of the responses of isolated vascular tissue to tyramine and sympathetic nerve stimulation. (1968) (0)
Central cholecystokinin antagonists to treat psychiatric diseases. (1990) (0)
Cholecystokinin receptor antagonists (1992) (0)

This paper list is powered by the following services:

Other Resources About John Hughes

en.wikipedia.org

What Schools Are Affiliated With John Hughes ?

John Hughes is affiliated with the following schools:

John Hughes 's Academic­Influence.com Rankings